Diabetes/Weight-Loss Drugs Expected To Be Negotiated Next, CMS Faces Hit If Coverage Expanded

Health policy experts predict popular diabetes and weight-loss treatments Ozempic and Wegovy could be next in line for CMS to negotiate Part D prices, as yet another study emerged this week predicting a huge financial hit to Medicare were Congress to lift the ban on CMS covering the drugs for weight-loss indications. A new Health Affairs study by health economists Benedic Ippolito and Joseph Levy says Part D would see a significant rise in costs if it decided cover...